Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 97,116

Document Document Title
WO/2014/100228A1
The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorde...  
WO/2014/100624A1
A stable, non-aqueous, liquid pharmaceutical composition contains remifentanil dissolved in a non-aqueous solvent. The formulation is provided with a pH ranging from about 2.0 to about 3.5 and can be used as an injectable. A method for p...  
WO/2014/098249A1
The purpose of the present invention is to provide a composition having a tissue repairing activity that is capable of promoting a reaction relating to tissue repairing. Disclosed is a composition having an activity of repairing a tissue...  
WO/2014/095775A1
The invention concerns BET-protein-inhibiting, in particular BRD4-inhibiting, dihydroquinoxalinones of general formula (I), in which A, X, R1, R2, R3, R4, R5, R6, R7 and n have the meanings given in the description, intermediates for pro...  
WO/2014/098512A1
The present invention relates to a novel use of fucosterol for the treatment of neurodegenerative diseases, and more particularly, to a pharmaceutical composition and functional health food comprising fucosterol, as an active ingredient,...  
WO/2014/099696A1
The present invention is directed to 2-pyridyloxy-4-ester compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ester compounds described herein in the potential treatme...  
WO/2014/094664A1
The present invention belongs to the technical field of medicines, and relates to a crystal form of a compound used as a mineralocorticoid receptor antagonist and a preparation method therefor, and in particular, to a method for preparin...  
WO/2014/100438A1
The present invention provides compounds of formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein W, X, n, s, t, and Ra are as described herein. The present invention relates generally to selective inhib...  
WO/2014/100600A3
Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The a...  
WO/2014/100540A1
The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.  
WO/2014/100833A1
Benzamide compounds and derivatives thereof, as can be used for selective inhibition of the SIRT2 enzyme and/or therapeutic use in the treatment of Huntington's disease.  
WO/2014/100359A1
Provided herein are 8'-Hydroxy-2-CF3-dihydroergotamine (8 ' OH-2-CF3 -DHE) compounds, compositions, and dosage forms containing such compositions. Also provided herein are methods of treatment, prevention, or amelioration of a variety of...  
WO/2014/094632A1
A pharmaceutical composition for treating headache, prepared from eleven Chinese herbal medicines: Chinese angelica root, ligusticum chuanxiong, radix paeoniae lactiflorae, prepared rhizome of rehmannia, uncaria tomentosa, leatherleaf mi...  
WO/2014/096212A1
The present invention is concerned with novel tricyclic 3,4-dihydro-2H-pyrido[l,2-a]pyrazine-l,6-dione derivatives of Formula (I) wherein R1, R2, R3, R4, L, Y, Z and X have the meaning defined in the claims. The compounds according to th...  
WO/2014/096377A1
New hydroxy aliphatic substituted phenyl aminoalkyi ether compounds of formula (I), compositions thereof and their use as a medicament in the treatment of nervous system diseases and/or the treatment of developmental, behavioral and/or m...  
WO/2014/096941A1
The present disclosure provides cyclic sulfonamides of Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3a, R3b, and n are defined as set forth in the specification. The present disclosure is ...  
WO/2014/090515A1
The present invention relates to an algal extract comprising sulphated and non-sulphated polyanionic polysaccharides, to a method for preparing an algal extract, and also to the therapeutic and prophylactic uses thereof.  
WO/2014/089913A1
The present invention relates to a compound shown in a formula (I), a method for preparing the compound, a pharmaceutical composition containing the compound, and applications of the compound in preparing drugs for preventing and/or trea...  
WO/2014/090990A1
The invention relates to a pharmaceutical composition comprising a leukotriene antagonist or a leukotriene receptor antagonist for the treatment of a subject suffering from dementia in Parkinson's disease. Further, the invention provides...  
WO/2014/092006A1
[Problem] To provide a novel compound that exhibits an agonistic effect on dopamine D2 receptors. [Solution] A compound that can be represented by general formula (I) (in which R1 represents a C1-6 alkyl or the like; R2 represents hydrog...  
WO/2014/092104A1
The invention provides compounds represented by formula (1) (in the formula, Het represents the formula (Het-1) or the like; A represents the formula (A-1) or the like; B represents (B-1) or the like; R1A represents a hydrogen atom, alky...  
WO/2014/093114A8
The present invention relates to PPARy- sparing compounds and pharmaceutical compositions formulated with such compounds that are useful for treating, delaying the onset of, or reducing the symptoms of a neurodegenerative disorder includ...  
WO/2014/090929A1
Pharmaceutical compositions comprising vortioxetine and donepezil are provided and the use of such composition for the treatment of cognitive dysfunctions.  
WO/2014/093791A1
Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use...  
WO/2014/092175A1
The present invention addresses the problem of providing a method for manufacturing a comparatively high-purity ≥4-mer polyphenol by precisely isolating said ≥4-mer polyphenol from a polyphenol mixture. This method for manufacturing ...  
WO/2014/091876A1
The fluorine-substituted piperidine compound represented in formula (I) or a pharmaceutically acceptable salt thereof is useful in the treatment or prevention of disorders that are on the basis of orexin (OX) receptor antagonism includin...  
WO/2014/091388A3
The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activ...  
WO/2014/093114A1
The present invention relates to PPARy- sparing compounds and pharmaceutical compositions formulated with such compounds that are useful for treating, delaying the onset of, or reducing the symptoms of a neurodegenerative disorder includ...  
WO/2014/091415A1
The invention relates to indole carboxamide derivatives of formula (I), (I) wherein R1, R 2, R 3, R 4, R5 and R6 are as defined in the description, their preparation and their use as pharmaceutically active compounds.  
WO/2014/092227A1
The present invention relates to a composition for treatment of diseases related to the removal of extracellular alpha-synuclein and to a method for screening a therapeutic agent for said diseases.  
WO/2014/090921A1
The invention relates to a method of treating pain in a patient by applying a transdermal therapeutic system for the transdermal administration of buprenorphine for 7 days on the skin of a patient, said transdermal therapeutic system com...  
WO/2014/091352A1
The present invention provides compounds of Formula (I), and the tautomers thereof, and the pharmaceutically acceptable salts of the compounds and tautomers, wherein the compounds have the structure (I) wherein the variables R1, R2, R3, ...  
WO/2014/093901A1
Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.  
WO/2014/093871A1
The present invention relates to methods for treating pruritus with anti-pruritic compositions.  
WO/2014/092100A1
The purpose of the invention is to provide a compound or salt thereof that is useful as an agent for the prevention or treatment of epilepsy, neurodegenerative disease, and the like. The invention pertains to compounds represented by for...  
WO/2014/093918A1
The disclosure provides compositions, methods and kits for treatment of neuronal injury. In one embodiment, the composition comprises polyethylene glycol (PEG), and magnesium in one composition. In another embodiment, the composition com...  
WO/2014/093475A1
Provided herein are methods and compositions for treatment of patients with Parkinson's disease and, in particular, motor impairments in patients with Parkinson's disease, using an aminopyridine.  
WO/2014/089620A1
The present invention provides compositions comprising a combination of: (i) one or more B vitamins or alternative form(s), derivative(s), or salt(s) thereof, or combinations thereof, and/or source(s) thereof; and (ii) phosphatidylserine...  
WO/2014/093190A1
In its many embodiments, the present invention provides certain C2-ring-substituted iminothiadiazine compounds, or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and said tautomers. The novel compounds of th...  
WO/2014/093277A1
The present invention relates generally to the fields of treating psychiatric disorders, in particular, anxiety disorders including post-traumatic stress disorder (PTSD) in subjects, e.g., human subjects, by administering a xenon and/or ...  
WO/2014/091020A1
The present invention refers to phenanthrene derivatives for use as medicaments, in the prevention and/or treatment of Myotonic Dystrophy Type 1, Huntington's Disease Like 2, Spinocerebellar Ataxia Type 8, Myotonic Dystrophy Type 2, Spin...  
WO/2014/093251A1
Engineered chloride channel receptors, nucleic acids encoding these receptors, expression vectors including these nucleic acids are disclosed herein. Nanoparticles and pharmaceutical compositions including these engineered chloride chann...  
WO/2014/086098A1
Disclosed are a cyclohexane amine compound and an application thereof for anti-schizophrenia drugs. The cyclohexane amine compound of the present invention has high affinity for a dopamine D3 receptor and 5-ΗΤ1Α, and a lead compound h...  
WO/2014/089480A1
The present specification provides immunosuppressive Tat derivative polypeptides, compositions, and methods of using such polypeptides and compositions to treat an autoimmune disease, an inflammation-associated disease and/or a neurodege...  
WO/2014/089209A2
Engineered multivalent and multispecific binding proteins capable of penetrating the blood-brain barrier (BBB) are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.  
WO/2014/088932A1
Provided herein are methods of treatment of individuals having schizophrenia, or schizophreniform disorder, using angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising...  
WO/2014/086104A1
The present invention relates to the field of drugs, and more particularly to an AMPK activator and an application thereof in preparing drugs for treating and/or preventing diabetes and/or diabetes complications. The present invention pr...  
WO/2014/087165A1
The present invention relates to a compound of formula I wherein X is C(R6) or N, Y is C or N, and ring A, ring B, R1 and R2 have the meanings defined herein, provided that when ring B is carbocyclic, X is C(R6); or a pharmaceutically ac...  
WO/2014/087367A3
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount ...  
WO/2014/087110A1
A method for the industrial synthesis of an addition salt with a pharmaceutically acceptable acid of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benz amide of formula (I), in which ΗΧ represents a pharmaceutically acceptabl...  

Matches 401 - 450 out of 97,116